The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
As Tracky launches integrated health solution
The Trust’s shift from single-use compostable cups to a reusable system was driven by the need to reduce environmental impact and control long-term costs
Subscribe To Our Newsletter & Stay Updated
